Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 31, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Aetna Inc. (NYSE: AET), United Therapeutics Corporation (NASDAQ: UTHR), Perrigo Co. (NYSE: PRGO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Aetna Inc. Research Report
On December 19, 2013, Aetna Inc. (Aetna), along with Arizona Care Network, announced an accountable care collaboration and the introduction of Arizona Care Network Plans, an Aetna Whole HealthSM product. The Company informed that Aetna Whole Health is a collection of benefits plans to offer members access to highly coordinated care from the physicians and facilities in the Arizona Care Network. Aetna added that the health plans are designed for fully insured and self-insured employers in Maricopa County and can be availed beginning January 1, 2014. Tom Dameron, Company President for Arizona Operations, stated, "Working together, Aetna and Arizona Care Network will deliver high quality, comprehensive health care to our customers and their employees in Maricopa County. This agreement with Arizona Care Network is just the latest example of Aetna's commitment to working with medical providers across the country to provide better value and improved outcomes for our members." The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
United Therapeutics Corporation Research Report
On December 20, 2013, United Therapeutics Corporation (United Therapeutics) announced that its Orenitram (treprostinil) Extended-Release Tablets have been approved by the United States Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. Commenting on the approval, Roger Jeffs, Ph.D., President and Chief Operating Officer of United Therapeutics stated, "This approval marks the first time that the FDA has approved an orally administered prostacyclin analogue for any disease - and our fifth approval from the FDA for treatment of PAH - supporting our mission of providing a wider choice of PAH therapies for physicians and patients. We are grateful for the FDA's thorough review and will continue to build clinical support for the use of Orenitram." The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Perrigo Co. Research Report
On December 18, 2013, Perrigo Co. (Perrigo) announced that the Company has appointed Board of Directors, effective until its annual general meeting on November 2014. The Company informed that Joseph C. Papa, President and CEO of the Company, has been named Chairman of the Board, and Gary K. Kunkle, Jr., has been named Lead Independent Director. Perrigo added that Mr. Papa will head an 11-member Board that will include all of the former members of the Perrigo Board of Directors. The Company stated that the appointment of the Company's Board follows the completion of its acquisition of Elan Corporation, plc, in a transaction valued at approximately $8.6 billion. The Full Research Report on Perrigo Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Arena Pharmaceuticals, Inc. Research Report
On December 26, 2013, Arena Pharmaceuticals, Inc.'s (Arena Pharmaceuticals) stock went up by 6.03%, to close at $5.98. The Company's stock went rose 7.36% over the previous three trading sessions, compared to the Dow Jones Industrial Average, which advanced 1.60% during the same trading period. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Keryx Biopharmaceuticals Inc. Research Report
On December 18, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,609,896, which will expire in 2024. According to the Company, the patent claims orally administrable forms of Zerenex prepared from ferric citrate having a BET active surface area greater than about 16 sq. m/g. Keryx informed that the active pharmaceutical ingredient of Zerenex is ferric citrate having a BET surface area substantially above this surface area threshold. Ron Bentsur, CEO of Keryx, commented, "We believe that our portfolio of patents will provide market exclusivity for Zerenex through at least 2024, as the high API surface area of our ferric citrate is essential for Zerenex' activity and dissolution. The patent issued today enhances our IP portfolio through the protection of orally administrable forms of Zerenex." The Company added that its New Drug Application for Zerenex is presently under review by the Food and Drug Administration with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner